NUWE
NASDAQNuwellis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Website
News25/Ratings1
News · 26 weeks400%
2025-10-262026-04-19
Mix3190d
- SEC Filings12(39%)
- Other9(29%)
- Insider5(16%)
- Leadership3(10%)
- Earnings2(6%)
Latest news
25 items- PRNuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring RetreatMINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the start of the event, Nuwellis will attend the ERAS Cardiac Spring Retreat gathering of thought leaders, to discuss best practices and innovation in cardiac surgery care. "AATS is one of the largest congresses in the cardiothoracic arena, and a unique opportunity to showcase our Aquadex technology, and
- PRNuwellis Announces Aquadex Software UpdateMINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience. A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, where small-volume fluid shifts can have a significant clinical impact. "The Aquadex software update reflects our commitment to con
- PRNuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical MomentumMINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the return of three former team members: Liby Cielo, Principal Account Manager; Meredith Stein, Senior Clinical Education Specialist; and Scott Campbell, Area Vice President, Sales. The addition of these returning team members reflects Nuwellis' continued focus on strengthening its commercial and clinical capabilities and supporting hospitals treating patients with complex cardiorenal conditions. "Welcoming back Liby, Meredith, and Scott reflects the strength of our team and the culture we are build
- PRNuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management ServicesMINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services. Nuwellis Chairman and CEO John Erb commented, "We believe CORE IR's integrated communications approach will enable us to more effectively articulate our value proposition to investors, partners, and key stakeholders. As we continue to expand our presence across the medical device and diag
- PRNuwellis Strengthens Commercial Infrastructure with New South Texas TerritoryMINNEAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets. South Texas is a significant healthcare region with large hospital systems and leading cardiac and critical care programs managing patients with complex fluid balance challenges. By establishing a focused territory, Nuwellis aims to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies
- SECSEC Form DEFA14A filed by Nuwellis Inc.DEFA14A - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form DEF 14A filed by Nuwellis Inc.DEF 14A - Nuwellis, Inc. (0001506492) (Filer)
- SECAmendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth MilestoneMINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company's largest and fastest-growing category and represents approximately 50% of total U.S. revenue. "Our pediatric category has become a meaningful and durable driver of growth, now accounting for approximately half of total revenue in 2025. This is a significant milestone as it both demonstrates the importance of the pediatric utilization of Aquadex, and the flexibility of the device across multiple patient demographics," said Nuwell
- SECNuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- INSIDERSEC Form 3 filed by new insider Emerson Martin J3 - Nuwellis, Inc. (0001506492) (Issuer)
- SECNuwellis Inc. filed SEC Form 8-K: Other Events8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Completes Acquisition of RendiatechMINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card
- SECSEC Form 10-K filed by Nuwellis Inc.10-K - Nuwellis, Inc. (0001506492) (Filer)
- SECNuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial ResultsMINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p
- PRNuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal StrategyMINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand
- INSIDERSEC Form 3 filed by new insider Mcdonald David3 - Nuwellis, Inc. (0001506492) (Issuer)
- SECNuwellis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Appoints David A. McDonald and Martin J. Emerson to Board of DirectorsMINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali
- PRNuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N
- INSIDERSEC Form 3 filed by new insider Schultz Carisa3 - Nuwellis, Inc. (0001506492) (Issuer)
- INSIDERSEC Form 3 filed by new insider Field Katharyn3 - Nuwellis, Inc. (0001506492) (Issuer)
- INSIDERSEC Form 3 filed by new insider Grasso Mika3 - Nuwellis, Inc. (0001506492) (Issuer)
- SECSEC Form EFFECT filed by Nuwellis Inc.EFFECT - Nuwellis, Inc. (0001506492) (Filer)